Ginkgo Bioworks completed the acquisition of Patch Biosciences from a16z Bio + Health, Casdin Capital and Section 32.

Ginkgo Bioworks, a platform for cell programming and biosecurity, completed the acquisition of Patch Biosciences, an AI platform for sequence design that enables more effective, specific, and durable genetic medicines, from a16z Bio + Health, a company that invests in tech-forward healthcare entrepreneurs and innovators, Casdin Capital, a New York-based research investment firm, and Section 32, a venture capital fund investing at the frontiers of technology and healthcare. Financial terms were not disclosed. "Patch has built an excellent team and platform which we are excited to welcome to Ginkgo. Integrating Patch's capabilities, libraries, and datasets is immediately valuable to our on-going programs and augments the genetic medicine toolkit we have built for our customers. We want to bring a unified R&D experience to our customers and offering integrated services that include specialized assets like Patch's allow our customers to tap into a broader-than-ever capability set," Jason Kelly, Ginkgo Bioworks CEO and Co-Founder.